Replimune Group (REPL) Stock Forecast & Price Target

$12.49 +0.48 (+4.00%)

(As of 12/20/2024 05:16 PM ET)

Replimune Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 8 Analyst Ratings

Sell
0

Hold
0

Buy
8

Based on 8 Wall Street analysts who have issued ratings for Replimune Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 7 have given a buy rating, and 1 has given a strong buy rating for REPL.

Consensus Price Target

$17.29
38.40% Upside

According to the 8 analysts' twelve-month price targets for Replimune Group, the average price target is $17.29. The highest price target for REPL is $19.00, while the lowest price target for REPL is $16.00. The average price target represents a forecasted upside of 38.40% from the current price of $12.49.

Get the Latest News and Ratings for REPL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Replimune Group and its competitors.

REPL Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$17.29	$16.80	$16.20	$43.40
Forecasted Upside	38.40% Upside	52.04% Upside	48.49% Upside	432.52% Upside
Consensus Rating	Buy	Buy	Buy	Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

>> Register for the Workshop Now

REPL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

REPL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Replimune Group Stock vs. The Competition

Type	Replimune Group	Medical Companies	S&P 500
Consensus Rating Score	3.13	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	38.40% Upside	25,828.93% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent REPL News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/4/2024	Jefferies Financial Group 2 of 5 stars		Boost Target	Buy ➝ Buy	$16.00 ➝ $19.00	+44.60%
11/22/2024	BMO Capital Markets 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$14.00 ➝ $18.00	+12.99%
11/22/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00	+53.85%
9/24/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$14.00 ➝ $17.00	+52.60%
8/27/2024	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Paluch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/27/2024	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$17.00	+70.17%
6/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$13.00 ➝ $17.00	+125.17%
6/6/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$16.00	+125.03%
4/17/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight	$44.00	+159.28%
1/5/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$60.00	+128.57%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:44 AM ET.

REPL Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Replimune Group is $17.29, with a high forecast of $19.00 and a low forecast of $16.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" REPL shares.
: According to analysts, Replimune Group's stock has a predicted upside of 38.40% based on their 12-month stock forecasts.
: Replimune Group has been rated by research analysts at BMO Capital Markets, HC Wainwright, Jefferies Financial Group, and JPMorgan Chase & Co. in the past 90 days.
: Analysts like Replimune Group more than other "medical" companies. The consensus rating for Replimune Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how REPL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

>> Register for the Workshop Now

This page (NASDAQ:REPL) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Replimune Group (REPL) Stock Forecast & Price Target